Research-based biopharmaceutical company Seragon Biosciences Inc announced on Wednesday the publication of comprehensive preclinical study results in the peer-reviewed journal Drug Design, Development and Therapy, demonstrating that its investigational combinatorial longevity drug, SRN-901, significantly extended median remaining lifespan and attenuated frailty progression in adult mice.

According to the company, the published study highlights the potential of SRN-901 as a multi-target combinatorial approach to promote healthy aging and extend lifespan by targeting multiple aging pathways.

The oral therapy extended median remaining lifespan in adult mice by 33% compared to placebo. Findings also showed that treatment resulted in a 70% attenuation of frailty progression and 30.53% reduction in tumor incidence, highlighting significant improvements in physiological resilience.

SRN-901 is a novel oral combinatorial drug consisting of advanced longevity-associated compounds and Seragon's SRN-820. The combination acts as a multi-target intervention designed to simultaneously modulate interconnected nutrient-sensing, mitochondrial surveillance, and stress-response networks.